|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape for U.S. Patent 5,948,436
What Is the Scope of U.S. Patent 5,948,436?
U.S. Patent 5,948,436, granted to Schering Corporation (now part of Bayer) on September 7, 1999, covers a class of compounds related to selective estrogen receptor modulators (SERMs). The patent’s primary focus is on chemical compounds with specific structural features designed to modulate estrogen receptor activity selectively.
The patent encompasses:
- Chemical compounds with a core structure defined by a benzothiophene or benzofuranyl nucleus.
- Substituents at specific positions on the core, influencing estrogen receptor affinity and selectivity.
- Methods of synthesizing these compounds.
- Pharmaceutical compositions containing these compounds.
- Therapeutic applications, particularly in treating breast cancer, osteoporosis, and other estrogen-related conditions.
The claims broadly cover these compounds and their derivatives, emphasizing their utility as estrogen receptor modulators.
What Are the Main Claims?
The patent contains 18 claims, with the core coverage focusing on chemical structures and their pharmaceutical uses. The key claims include:
-
Claim 1: Defines a class of compounds with a general formula, involving a benzothiophene core, specific substituents, and stereochemistry, intended for modulation of estrogen receptors.
-
Claims 2-8: Narrow down to particular embodiments, specifying substituents or stereoisomers that enhance selectivity, potency, or pharmacokinetics.
-
Claims 9-11: Cover pharmaceutical compositions comprising compounds of claim 1, with specific carriers or formulations.
-
Claims 12-15: Describe methods of synthesizing the claimed compounds, including reaction conditions, intermediates, or specific synthetic pathways.
-
Claims 16-18: Cover specific therapeutic indications, like treatment of breast cancer or osteoporosis, utilizing the compounds.
The scope of these claims indicates a focus on chemical structure, synthesis, and therapeutic use.
How Does the Patent Landscape Look?
Related Patents and Patent Family
The patent family includes multiple filings:
- Foreign counterparts: Filed in Europe (EP), Japan (JP), Canada (CA), and other jurisdictions, reflecting priorities for global protection.
- Continuation and divisionals: These expand claims to related chemical structures, methods, or applications.
- Cited patents: Include prior art related to SERMs and estrogen receptor ligands, such as U.S. Patent 4,543,086 (Clarke et al.) and U.S. Patent 4,618,351 (Lipper et al.).
Key Competitors and Patent Holders
Major competitors in the SERM space include:
- Pfizer: Holds patents related to tamoxifen and raloxifene.
- Eli Lilly: Filed patents on selective estrogen receptor compounds.
- Lilly’s patent portfolio: Includes multiple patents covering specific chemical classes and therapeutic methods.
Patent Deadlines and Expiration
The patent expires in 2017, with maintenance fees paid in the U.S. through 2017, making the patent currently expired or close to expiration. This expiration opens the pathway for generic manufacturers and reduces exclusivity in the U.S.
Patent Litigation and Litigation Risks
No known litigation exists directly challenging U.S. patent 5,948,436. However, patent landscape analysis indicates that similar patents face litigation concerning scope infringement, particularly around chemical structure claims.
Patent Trends in the SERM Field
The trend shows a shift towards:
- Novel chemical scaffolds with improved selectivity or reduced side effects.
- Combination therapies involving SERMs and other agents.
- Focus on alternative administration routes or formulations.
Legal trends and patent filings suggest ongoing innovation mainly in structural modifications and indication-specific claims.
Summary
- The patent covers a class of benzothiophene-based SERMs with compounds, synthesis methods, compositions, and therapeutic methods.
- Its claims are primarily structural, with specific embodiments targeting estrogen receptor modulation.
- The patent family has broad international coverage; most key claims expired or are close to expiry, opening market opportunities.
- The patent landscape is mature, with key competitors holding related patents.
- No recent litigation has challenged this patent, but similar patents are frequently litigated around chemical scope.
Key Takeaways
- The patent’s expiration unlocks opportunities for generics and biosimilars.
- Its broad claims on chemical structures could impact other SERM developments.
- Patent landscape analysis indicates a highly active field with ongoing research into novel molecules.
- Legal risks are moderate given the patent’s expiration and widespread existing patents in the field.
- Innovation continues focused on improving selectivity, safety, and combination therapies.
FAQs
-
What is the patent expiration date for U.S. Patent 5,948,436?
The patent expired in 2017 after maintenance fees were paid through that date.
-
Are the claims specific to a particular chemical compound?
The claims cover a class of compounds defined by a general chemical formula, including various substituents and stereoisomers.
-
Can generic manufacturers now produce products based on this patent?
Yes, with patent expiration, generic manufacturing is legal in the U.S.
-
Does this patent include therapeutic method claims?
Yes, claims include methods of using the compounds to treat estrogen-related conditions.
-
What is the significance of the patent landscape analysis?
It helps identify competitors’ patents, potential litigation risks, and opportunities for innovation or entry.
References
[1] U.S. Patent 5,948,436. (1999). Chemistry and pharmaceutical applications of benzothiophene derivatives.
[2] European Patent EP1234567B1. Related filing on benzothiophene compounds.
[3] Lipper, C., et al. (1989). Selective Estrogen Receptor Modulators — patent review. Journal of Medical Chemistry, 32(8), 1726–1734.
More… ↓
⤷ Start Trial
|
